查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球中央實驗室服務/臨床試驗化驗服務市場按階段、服務類型、治療領域、方式、最終用戶和地區分類 - 預測至 2030 年
市場調查報告書
商品編碼
1684188

全球中央實驗室服務/臨床試驗化驗服務市場按階段、服務類型、治療領域、方式、最終用戶和地區分類 - 預測至 2030 年

Central Lab Services/Clinical Trial Lab Services Market by Phase (Phase I, II, III), Service Type (Safety Testing, Immunology), Therapeutic Area (Oncology), Modality (Small Molecules, Vaccine), End user (Pharma & CROs) & Region - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 311 Pages | 訂單完成後即時交付

價格

全球中央實驗室服務/臨床試驗化驗服務市場預計將從 2025 年的 59.7 億美元成長到 2030 年的 81.8 億美元，預測期內的複合年成長率為 6.5%。

研究範圍
調查年份 2024-2030
基準年 2024
預測期 2024-2030
考慮單位 金額（十億美元）
部分 按階段、按服務類型、按治療領域、按方式、按最終用戶、按地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

這是因為藥物研發的應用越來越廣泛，而且隨著應用的增加，對這些服務的需求也不斷增加。此外，政府對醫療保健提供的津貼不斷增加，也增加了臨床試驗的數量，從而增加了對中心實驗室臨床服務測試的需求。然而，臨床試驗方法的高成本是市場發展的主要限制因素。此外，訓練有素的醫療保健專業人員的短缺以及對服務的了解有限是市場成長的主要挑戰。然而，在 2025-2030 年的預測期內，市場擴張的條件正在形成。

根據最終用戶，中央實驗室服務/臨床試驗化驗服務市場細分為製藥和生物製藥公司、CROS、醫療設備公司和其他最終用戶。其中，製藥和生物製藥公司將在2024年佔據中央實驗室服務/臨床試驗化驗服務市場最大的市場佔有率，為61.8%。這是因為罕見疾病的盛行率正在增加。大多數製藥公司正在進行臨床試驗，利用先進技術治療此類疾病。這就是為什麼大多數企業更喜歡使用這些服務。因此，隨著這些疾病的盛行率上升，長期治療的需求也隨之增加，導致對中央實驗室服務/臨床試驗化驗服務市場的需求增加。

中央實驗室服務/臨床試驗化驗服務市場根據治療領域細分為腫瘤學、感染疾病、神經病學、心臟病學和其他治療領域。在中央實驗室服務/臨床試驗化驗服務市場中，由於癌症患者數量的增加，腫瘤科領域佔據了最大的市場佔有率。腫瘤臨床試驗通常需要先進的診斷測試，包括生物標記測試、基因組測試和腫瘤分析，以評估臨床試驗中新型癌症治療的有效性和安全性。中央實驗室在提供這些服務方面發揮著至關重要的作用，確保測試可行、一致且符合多個設施的監管標準。隨著精準醫療不斷受到關注，腫瘤領域對專業化、高品質實驗室檢測的需求龐大，使其成為中央實驗室服務市場中最大、最重要的領域。

亞太地區是中央實驗室服務/臨床試驗化驗服務成長最快的區域市場，預計在市場估計和預測期內將以最高的複合年成長率成長。這是由於全部區域所致。亞太地區包括日本、中國、印度等。其中，中國將在2024年佔據中心實驗室服務/臨床試驗化驗服務市場最大的市場佔有率，這得益於製藥和生物技術行業的快速擴張，以及龐大的患者群體和對創新治療的需求不斷成長。該國不斷發展的醫療保健基礎設施、對臨床研究的投資以及良好的法規環境使其成為全球臨床試驗的理想之地。

本報告研究了全球中央實驗室服務/臨床試驗化驗服務市場，按階段、服務類型、治療領域、方式、最終用戶、區域趨勢和參與市場的公司概況進行細分。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章 市場概況

  • 介紹
  • 市場動態
  • 影響客戶業務的趨勢/中斷
  • 價值鏈分析
  • 生態系分析
  • 投資金籌措場景
  • 技術分析
  • 2025-2026 年重要會議與活動
  • 案例研究分析
  • 監管狀態
  • 波特五力分析
  • 主要相關人員和採購標準
  • 人工智慧/生成式人工智慧對中央實驗室服務/臨床試驗化驗服務市場的影響

6. 中央實驗室服務/臨床試驗化驗服務市場（按階段分類）

  • 介紹
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

7. 中央實驗室服務/臨床試驗化驗服務市場（依服務類型）

  • 介紹
  • 安全測試
  • 免疫
  • 基因檢測
  • 血液凝固檢驗
  • 病理檢查
  • 生物標記
  • 伴同性診斷
  • 其他

8. 中央實驗室服務/臨床試驗化驗服務市場（依治療領域）

  • 介紹
  • 瘤
  • 感染疾病
  • 神經
  • 心臟病
  • 其他

9. 中央實驗室服務/臨床試驗化驗服務市場（按方式）

  • 介紹
  • 小分子
  • 生物學
  • 細胞和基因治療
  • 醫療設備及體外診斷設備

10. 中央實驗室服務/臨床試驗化驗服務市場（依最終使用者分類）

  • 介紹
  • 製藥和生物製藥公司
  • 臨床研究組織
  • 醫療設備公司
  • 其他

11. 中央實驗室服務/臨床試驗化驗服務市場（按地區）

  • 介紹
  • 北美洲
    • 北美宏觀經濟展望
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲宏觀經濟展望
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 亞太宏觀經濟展望
    • 日本
    • 中國
    • 印度
    • 其他
  • 拉丁美洲
  • 中東和非洲

第12章 競爭格局

  • 概述
  • 主要參與企業的策略/優勢
  • 2020 年至 2024 年收益分析
  • 2024 年市場佔有率分析
  • 企業估值與財務指標
  • 品牌/產品比較
  • 公司估值矩陣：主要參與企業，2024 年
  • 公司估值矩陣：Start-Ups/中小企業，2024 年
  • 競爭場景

第13章 公司簡介

  • 主要參與企業
    • THERMO FISHER SCIENTIFIC INC.
    • IQVIA
    • ICON PLC
    • CHARLES RIVER LABORATORIES
    • LABCORP
    • QUEST DIAGNOSTICS
    • MEDPACE
    • FRONTAGE LABS
    • SGS SOCIETE GENERALE DE SURVEILLANCE SA
    • EUROFINS SCIENTIFIC
    • REPROCELL INC.
    • ACM GLOBAL LABORATORIES
  • 其他公司
    • WORLDWIDE CLINICAL TRIALS
    • VERSITI
    • CTI CLINICAL TRIAL & CONSULTING
    • CLARITY LABORATORIES, INC
    • NOVOTECH
    • ARUP LABORATORIES
    • PRECISION MEDICINE GROUP
    • BIOAGILYTIX LABS
    • CERBA HEALTHCARE
    • ALMAC GROUP
    • MLM MEDICAL LABS
    • SALVUS BIORESEARCH SOLUTIONS LLP
    • UNILABS

第14章 附錄

Product Code: PH 9332

The global Central lab services/clinical trial lab services market is projected to reach USD 8.18 billion by 2030 from USD 5.97 billion in 2025, at a CAGR of 6.5% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD billion)
SegmentsPhase, Service Type, Therapeutic Area, Application,End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa

This is due to increasing adoption of drug discovery, as the adoption increases the demand for these services rises. Additionally, increasing government support to provide grants for healthcare is increasing, thus rising the number of clinical trials, consequently increasing the demand for the central lab clinical service trial. However, the high cost associated with the clinical trial methods are the major restraint to the market. Additionally, the shortage of trained healthcare professionals & limited knowledge about the services is major challenge for the market growth. But is creating a conducive environment for market expansion over the forecast period of 2025-2030.

"The pharmaceutical & biopharmaceutical companies segment of central lab services/clinical trial lab services market by end user to hold largest position forecast period."

Based on the end user, the central lab services/clinical trial lab services market is divided into pharmaceutical & biopharmaceutical companies, CROS, medical device companies, and other end users. Among these, in 2024 pharmaceutical & biopharmaceutical companie segment account for the largest market share of 61.8% in central lab services/clinical trial lab services market. This is due to the rising prevalence of rare disease. Majority of the pharmaceutical companies are conducting the clinical trials for the cure of such diseases via advanced technologies. Thus, majority of the companies prefer these services. Thus, as the prevalence of these diseases is increasing the need for long term treatment is rising, consequently increasing the demand for central lab services/clinical trial lab services market.

"The oncology segment accounts for the largest market share in central lab services/clinical trial lab services market."

Based on theraprutic area, the central lab services/clinical trial lab services market is segmented into oncology, infectious diseases, neurology, cardiology, and other therapeutic areas. The oncology segment holds for the largest market share in central lab services/clinical trial lab services market due to increasing number of cancer patients. Oncology clinical trials often require modern diagnostic testing, including biomarker testing, genomic testing, and tumor profiling, to assess the effectiveness and safety of new cancer therapies in clinical trials. Central labs are important in providing these services, ensuring that testing is viable, consistent, and compliant with regulatory standards across multiple sites. With the rising focus on precision medicine, the need for specialized and high-quality lab testing in oncology is significant, making the oncology segment the largest and most critical in the central lab services market.

"Asia Pacific is the fastest growing region of the central lab services/clinical trial lab services market by region."

The global central lab services/clinical trial lab services market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing regional market for entral lab services/clinical trial lab services and is estimated to grow at the highest CAGR during the forecast period. This is due to increasing prevalence of rare diseases and rising population across the region. Asia Pacific region includes Japan, China, India, and Rest of Asia Pacific. Among these, China accounts for the largest market share in central lab services/clinical trial lab services market in 2024. This is due to its rapid expansion of pharmaceutical and biotechnology industries, added with the with a large patient population and increasing demand for innovative treatments. The country's growing healthcare infrastructure, investment in clinical research, and supportive regulatory environment have made it an attractive hub for global clinical trials.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-48%, Tier 2-36%, and Tier 3- 16%
  • By Designation: C-level-25%, Director-level-30% and Others-45%
  • By Region: North America-40%, Europe-25%, Asia Pacific-20%, Latin America- 10%, and Middle east and Africa - 5%

Note 1: Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the central lab services/clinical trial lab services market are Thermo Fisher Scientific Inc. (US), IQVIA (US), ICON plc (Ireland), Labcorp (US), Quest Diagnostics (US), Charles River Laboratories (US), Medpace (US), Frontage lab (US), SGS Societe Generale de Surveillance SA (Switzerland), Eurofins Scientific (Luxembourg), and REPROCELL Inc. (Japan).

Research Coverage

This report studies the central lab services/clinical trial lab services market based on product, type, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

  • Analysis of Key divers (Increasing number of clinical trials, increasing investments in research & development, growing prevalence of rare diseases), restraints (High cost associated with clinicaltrials, Shortage of skilled professionals), opportunity (Emerging markets worldwide, decentralized and virtual clinical trials), Challenge (regulatory complexities, limited patient diversity and cybersecurity or intellectual property concerns)
  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the central lab services/clinical trial lab services market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the central lab services/clinical trial lab services market
  • Market Development: Comprehensive information on lucrative emerging regions
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pain management devices market
  • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key industry insights
      • 2.1.2.3 Key data from primary sources
      • 2.1.2.4 Breakdown of primary interviews
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
      • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.2.1.3 Approach 3: Primary interviews
      • 2.2.1.4 Growth forecast
      • 2.2.1.5 CAGR projections
    • 2.2.2 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 RESEARCH ASSUMPTIONS
    • 2.4.1 STUDY-RELATED ASSUMPTIONS
    • 2.4.2 PARAMETRIC ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS
  • 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET OVERVIEW
  • 4.2 ASIA PACIFIC CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER AND COUNTRY
  • 4.3 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY
  • 4.4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, REGIONAL MIX, 2025 VS. 2030

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing number of clinical trials
      • 5.2.1.2 Rising investments in research & development
      • 5.2.1.3 Growing prevalence of rare diseases
      • 5.2.1.4 Favorable government initiatives
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High costs associated with clinical trials
      • 5.2.2.2 Shortage of skilled professionals
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging markets worldwide
      • 5.2.3.2 Decentralized and virtual clinical trials
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Regulatory complexities
      • 5.2.4.2 Limited patient diversity
      • 5.2.4.3 Cybersecurity and intellectual property concerns
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 VALUE CHAIN ANALYSIS
    • 5.4.1 RESOURCE ACQUISITION AND PREPARATION
    • 5.4.2 CLINICAL TRIAL EXECUTION
    • 5.4.3 DATA REPORTING AND RESULT SUBMISSION
    • 5.4.4 PROMOTION AND REGULATORY FILING
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 INVESTMENT AND FUNDING SCENARIO
  • 5.7 TECHNOLOGY ANALYSIS
    • 5.7.1 KEY TECHNOLOGIES
      • 5.7.1.1 Enzyme-linked immunosorbent assay
    • 5.7.2 ADJACENT TECHNOLOGIES
      • 5.7.2.1 Next-generation sequencing
  • 5.8 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.9 CASE STUDY ANALYSIS
    • 5.9.1 PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY AND SAFETY OF TWO COMBINATION THERAPIES (CERBA RESEARCH)
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY FRAMEWORK
      • 5.10.1.1 North America
      • 5.10.1.2 Europe
      • 5.10.1.3 Asia Pacific
      • 5.10.1.4 Rest of the World
    • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 THREAT OF NEW ENTRANTS
    • 5.11.2 THREAT OF SUBSTITUTES
    • 5.11.3 BARGAINING POWER OF SUPPLIERS
    • 5.11.4 BARGAINING POWER OF BUYERS
    • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.12.2 BUYING CRITERIA
  • 5.13 IMPACT OF AI/GENERATIVE AI ON CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
    • 5.13.1 INTRODUCTION
    • 5.13.2 MARKET POTENTIAL OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES
    • 5.13.3 AI USE CASES
    • 5.13.4 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL LAB ECOSYSTEM

6 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE

  • 6.1 INTRODUCTION
  • 6.2 PHASE I
    • 6.2.1 NEED TO ASSESS SAFETY, DOSAGE, AND POTENTIAL SIDE EFFECTS OF DRUGS TO AID GROWTH
  • 6.3 PHASE II
    • 6.3.1 NEED TO EVALUATE DESIRED EFFECT AND ADDITIONAL SAFETY DATA OF DRUGS TO DRIVE MARKET
  • 6.4 PHASE III
    • 6.4.1 RISING INCLINATION TOWARD CONFIRMING SAFETY AND EFFICACY OF DRUGS TO BOOST MARKET
  • 6.5 PHASE IV
    • 6.5.1 ONGOING SAFETY SURVEILLANCE ON DRUG TRIALS TO AUGMENT GROWTH

7 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE

  • 7.1 INTRODUCTION
  • 7.2 SAFETY TESTING
    • 7.2.1 NEED TO ENSURE COMPLIANCE WITH SAFETY STANDARDS TO PROMOTE GROWTH
  • 7.3 IMMUNOLOGY
    • 7.3.1 INCREASING FOCUS ON IMMUNOTHERAPIES TO STIMULATE GROWTH
  • 7.4 GENETIC TESTING
    • 7.4.1 GROWING ADVANCEMENTS IN NEXT-GENERATION SEQUENCING TO DRIVE MARKET
  • 7.5 COAGULATION TESTING
    • 7.5.1 ESSENTIAL ROLE IN MONITORING COAGULATION DISORDERS AND EVALUATING ANTICOAGULANT THERAPIES TO EXPEDITE GROWTH
  • 7.6 PATHOLOGY TESTING
    • 7.6.1 ABILITY TO PROVIDE INSIGHTS INTO DISEASE MECHANISMS, TREATMENT EFFECTS, AND DIAGNOSTICS TO AID GROWTH
  • 7.7 BIOMARKERS
    • 7.7.1 NEED TO EXAMINE TEST EFFECTS ON PATIENTS TO AUGMENT GROWTH
  • 7.8 COMPANION DIAGNOSTICS
    • 7.8.1 GROWING INCLINATION TOWARD PERSONALIZED TREATMENTS TO DRIVE MARKET
  • 7.9 OTHER TESTS

8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA

  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
    • 8.2.1 INCREASING CANCER RESEARCH STUDIES TO ACCELERATE GROWTH
  • 8.3 INFECTIOUS DISEASES
    • 8.3.1 INCREASING CASES OF INFECTIOUS DISEASES TO ENCOURAGE GROWTH
  • 8.4 NEUROLOGY
    • 8.4.1 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO FACILITATE GROWTH
  • 8.5 CARDIOLOGY
    • 8.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL MARKET
  • 8.6 OTHER THERAPEUTIC AREAS

9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY

  • 9.1 INTRODUCTION
  • 9.2 SMALL MOLECULES
    • 9.2.1 EMERGENCE OF THERAPEUTIC MODALITIES TO AMPLIFY GROWTH
  • 9.3 BIOLOGICS
    • 9.3.1 MONOCLONAL ANTIBODIES
      • 9.3.1.1 Growing advancements in antibody engineering to drive market
    • 9.3.2 VACCINES
      • 9.3.2.1 Increasing investments in vaccine development to favor growth
    • 9.3.3 OTHER THERAPEUTIC PRODUCTS
  • 9.4 CELL & GENE THERAPY
    • 9.4.1 OUTSOURCING TREND TO FAVOR GROWTH
  • 9.5 MEDICAL DEVICES & IVD DEVICES
    • 9.5.1 RISING FOCUS ON REAL-TIME PATIENT HEALTH TRACKING TO BOOST MARKET

10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 10.2.1 EMERGING BIOPHARMA COMPANIES TO EXPEDITE GROWTH
  • 10.3 CLINICAL RESEARCH ORGANIZATIONS
    • 10.3.1 CRITICAL ROLE IN SITE SELECTION, RECRUITMENT SUPPORT, CLINICAL MONITORING, AND DATA COLLECTION TO DRIVE MARKET
  • 10.4 MEDICAL DEVICE COMPANIES
    • 10.4.1 RISING FOCUS ON QUALITY AND SAFETY STANDARDS TO STIMULATE GROWTH
  • 10.5 OTHER END USERS

11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 Increasing clinical trials to support growth
    • 11.2.3 CANADA
      • 11.2.3.1 Rising incidence of chronic diseases to advance growth
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.3.2 GERMANY
      • 11.3.2.1 Increasing healthcare expenditure to intensify growth
    • 11.3.3 FRANCE
      • 11.3.3.1 Growing investments in life sciences sector to boost market
    • 11.3.4 UK
      • 11.3.4.1 High number of oncology clinical trials to facilitate growth
    • 11.3.5 ITALY
      • 11.3.5.1 Rising focus on streamlining clinical trial process to expedite growth
    • 11.3.6 SPAIN
      • 11.3.6.1 Emerging biotech companies to bolster growth
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.4.2 JAPAN
      • 11.4.2.1 Growing demand for drug development to propel market
    • 11.4.3 CHINA
      • 11.4.3.1 Booming pharmaceutical industry to drive market
    • 11.4.4 INDIA
      • 11.4.4.1 Increasing regulatory reforms to foster growth
    • 11.4.5 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 ROBUST MANUFACTURING INFRASTRUCTURE TO SUSTAIN GROWTH
    • 11.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO FUEL MARKET
    • 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
  • 12.3 REVENUE ANALYSIS, 2020-2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.6 BRAND/PRODUCT COMPARISON
  • 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 12.7.1 STARS
    • 12.7.2 EMERGING LEADERS
    • 12.7.3 PERVASIVE PLAYERS
    • 12.7.4 PARTICIPANTS
    • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 12.7.5.1 Company footprint
      • 12.7.5.2 Region footprint
      • 12.7.5.3 Product type footprint
      • 12.7.5.4 Therapeutic area footprint
      • 12.7.5.5 Phase footprint
  • 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 12.8.1 PROGRESSIVE COMPANIES
    • 12.8.2 RESPONSIVE COMPANIES
    • 12.8.3 DYNAMIC COMPANIES
    • 12.8.4 STARTING BLOCKS
    • 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 12.8.5.1 Detailed list of key startups/SMEs
      • 12.8.5.2 Competitive benchmarking of key startups/SMEs
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES
    • 12.9.2 DEALS
    • 12.9.3 EXPANSIONS
    • 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 THERMO FISHER SCIENTIFIC INC.
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products/Services offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Product launches
        • 13.1.1.3.2 Deals
        • 13.1.1.3.3 Expansions
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Key strengths
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses and competitive threats
    • 13.1.2 IQVIA
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products/Services offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Product launches
        • 13.1.2.3.2 Deals
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Right to win
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses and competitive threats
    • 13.1.3 ICON PLC
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products/Services offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product launches
        • 13.1.3.3.2 Deals
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Right to win
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses and competitive threats
    • 13.1.4 CHARLES RIVER LABORATORIES
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products/Services offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Deals
        • 13.1.4.3.2 Expansions
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Right to win
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses and competitive threats
    • 13.1.5 LABCORP
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products/Services offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Product launches
        • 13.1.5.3.2 Deals
        • 13.1.5.3.3 Expansions
        • 13.1.5.3.4 Other developments
      • 13.1.5.4 MnM view
        • 13.1.5.4.1 Key strengths
        • 13.1.5.4.2 Strategic choices
        • 13.1.5.4.3 Weaknesses and competitive threats
    • 13.1.6 QUEST DIAGNOSTICS
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products/Services offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Deals
    • 13.1.7 MEDPACE
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products/Services offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Expansions
    • 13.1.8 FRONTAGE LABS
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products/Services offered
    • 13.1.9 SGS SOCIETE GENERALE DE SURVEILLANCE SA
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products/Services offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Deals
    • 13.1.10 EUROFINS SCIENTIFIC
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products/Services offered
      • 13.1.10.3 Recent developments
        • 13.1.10.3.1 Deals
    • 13.1.11 REPROCELL INC.
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products/Services offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Deals
    • 13.1.12 ACM GLOBAL LABORATORIES
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products/Services offered
      • 13.1.12.3 Recent developments
        • 13.1.12.3.1 Deals
  • 13.2 OTHER PLAYERS
    • 13.2.1 WORLDWIDE CLINICAL TRIALS
    • 13.2.2 VERSITI
    • 13.2.3 CTI CLINICAL TRIAL & CONSULTING
    • 13.2.4 CLARITY LABORATORIES, INC
    • 13.2.5 NOVOTECH
    • 13.2.6 ARUP LABORATORIES
    • 13.2.7 PRECISION MEDICINE GROUP
    • 13.2.8 BIOAGILYTIX LABS
    • 13.2.9 CERBA HEALTHCARE
    • 13.2.10 ALMAC GROUP
    • 13.2.11 MLM MEDICAL LABS
    • 13.2.12 SALVUS BIORESEARCH SOLUTIONS LLP
    • 13.2.13 UNILABS

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: RISK ASSESSMENT
  • TABLE 3 TRADITIONAL VS. VIRTUAL CLINICAL TRIALS
  • TABLE 4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 5 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
  • TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES
  • TABLE 12 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
  • TABLE 14 KEY BUYING CRITERIA, BY END USER
  • TABLE 15 KEY COMPANIES IMPLEMENTING AI
  • TABLE 16 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 18 COMPANIES PROVIDING PHASE I SERVICES
  • TABLE 19 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 20 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 22 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 23 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 24 COMPANIES PROVIDING PHASE II SERVICES
  • TABLE 25 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 26 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 27 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 28 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 29 COMPANIES PROVIDING PHASE III SERVICES
  • TABLE 30 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 31 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 32 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 33 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 34 COMPANIES PROVIDING PHASE IV SERVICES
  • TABLE 35 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 36 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 37 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 39 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 40 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 41 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 42 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 44 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 45 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 46 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 48 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 49 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 50 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 52 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 53 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 54 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 56 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 57 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 58 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 60 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 61 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 62 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 64 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 65 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 66 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 68 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 69 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 70 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 72 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 73 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 74 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 75 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 77 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 78 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 79 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 81 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 82 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 83 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 85 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 86 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 87 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 89 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 90 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 91 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 92 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 93 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 94 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 95 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 96 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 97 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 98 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 99 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 100 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 101 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 103 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 104 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 105 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 106 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 107 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 108 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 109 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 111 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 112 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 113 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 115 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 116 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 117 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 119 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 120 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 121 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 123 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 124 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 125 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 126 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 128 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 129 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 130 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 132 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 133 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 134 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 136 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 137 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 138 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 139 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 140 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 141 MACROECONOMIC INDICATORS FOR NORTH AMERICA
  • TABLE 142 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 143 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 144 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 145 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 146 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 147 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 148 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 149 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 150 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 151 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 152 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 153 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 154 US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 155 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 156 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 157 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 158 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 159 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 160 CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 161 MACROECONOMIC INDICATORS FOR EUROPE
  • TABLE 162 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 163 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 164 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 165 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 166 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 167 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 168 EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 169 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 170 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 171 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 172 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 173 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 174 GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 175 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 176 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 177 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 178 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 179 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 180 FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 181 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 182 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 183 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 184 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 185 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 186 UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 187 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 188 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 189 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 190 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 191 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 192 ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 193 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 194 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 195 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 196 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 197 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 198 SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 199 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 200 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 201 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 202 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 203 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 204 REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 205 MACROECONOMIC INDICATORS FOR ASIA PACIFIC
  • TABLE 206 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 208 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 209 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 210 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 211 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 212 ASIA PACIFIC CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 213 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 214 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 215 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 216 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 217 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 218 JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 219 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 220 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 221 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 222 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 223 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 224 CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 225 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 226 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 227 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 228 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 229 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 230 INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 231 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 232 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 233 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 234 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 235 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 236 REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 237 MACROECONOMIC INDICATORS FOR LATIN AMERICA
  • TABLE 238 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 239 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 240 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 241 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 242 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 243 LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 244 MACROECONOMIC INDICATORS FOR MIDDLE EAST & AFRICA
  • TABLE 245 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 246 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022-2030 (USD MILLION)
  • TABLE 247 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION)
  • TABLE 248 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022-2030 (USD MILLION)
  • TABLE 249 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022-2030 (USD MILLION)
  • TABLE 250 MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 251 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, 2022-2025
  • TABLE 252 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DEGREE OF COMPETITION
  • TABLE 253 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: REGION FOOTPRINT
  • TABLE 254 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PRODUCT TYPE FOOTPRINT
  • TABLE 255 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: THERAPEUTIC AREA FOOTPRINT
  • TABLE 256 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PHASE FOOTPRINT
  • TABLE 257 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 258 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 259 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PRODUCT LAUNCHES, JANUARY 2022-JANUARY 2025
  • TABLE 260 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DEALS, JANUARY 2022-JANUARY 2025
  • TABLE 261 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: EXPANSIONS, JANUARY 2022-JANUARY 2025
  • TABLE 262 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2022-JANUARY 2025
  • TABLE 263 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 264 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 265 THERMO FISHER SCIENTIFIC INC: PRODUCT LAUNCHES, JANUARY 2022- JANUARY 2025
  • TABLE 266 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-JANUARY 2025
  • TABLE 267 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022-JANUARY 2025
  • TABLE 268 IQVIA: COMPANY OVERVIEW
  • TABLE 269 IQVIA: PRODUCTS/SERVICES OFFERED
  • TABLE 270 IQVIA: PRODUCT LAUNCHES, JANUARY 2022-JANUARY 2025
  • TABLE 271 IQVIA: DEALS, JANUARY 2022-JANUARY 2025
  • TABLE 272 ICON PLC: COMPANY OVERVIEW
  • TABLE 273 ICON PLC: PRODUCTS/SERVICES OFFERED
  • TABLE 274 ICON PLC: PRODUCT LAUNCHES, JANUARY 2022-JANUARY 2025
  • TABLE 275 ICON PLC: DEALS, JANUARY 2022-JANUARY 2025
  • TABLE 276 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
  • TABLE 277 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED
  • TABLE 278 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022-JANUARY 2025
  • TABLE 279 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022-JANUARY 2025
  • TABLE 280 LABCORP: COMPANY OVERVIEW
  • TABLE 281 LABCORP: PRODUCTS/SERVICES OFFERED
  • TABLE 282 LABCORP: PRODUCTS LAUNCHES, JANUARY 2022-JANUARY 2025
  • TABLE 283 LABCORP: DEALS, JANUARY 2022-JANUARY 2025
  • TABLE 284 LABCORP: EXPANSIONS, JANUARY 2022-JANUARY 2025
  • TABLE 285 LABCORP: OTHER DEVELOPMENTS, JANUARY 2022-JANUARY 2025
  • TABLE 286 QUEST DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 287 QUEST DIAGNOSTICS: PRODUCTS/SERVICES OFFERED
  • TABLE 288 QUEST DIAGNOSTICS: DEALS, JANUARY 2022-JANUARY 2025
  • TABLE 289 MEDPACE: COMPANY OVERVIEW
  • TABLE 290 MEDPACE: PRODUCTS/SERVICES OFFERED
  • TABLE 291 MEDPACE: EXPANSIONS, JANUARY 2022-JANUARY 2025
  • TABLE 292 FRONTAGE LABS: COMPANY OVERVIEW
  • TABLE 293 FRONTAGE LABS: PRODUCTS/SERVICES OFFERED
  • TABLE 294 SGS SOCIETE GENERALE DE SURVEILLANCE SA: COMPANY OVERVIEW
  • TABLE 295 SGS SOCIETE GENERALE DE SURVEILLANCE SA: PRODUCTS/SERVICES OFFERED
  • TABLE 296 SGS SOCIETE GENERALE DE SURVEILLANCE SA: DEALS, JANUARY 2022- JANUARY 2025
  • TABLE 297 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 298 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED
  • TABLE 299 EUROFINS SCIENTIFIC: DEALS, JANUARY 2022-JANUARY 2025
  • TABLE 300 REPROCELL INC.: COMPANY OVERVIEW
  • TABLE 301 REPROCELL INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 302 REPROCELL INC.: DEALS, JANUARY 2022-JANUARY 2025
  • TABLE 303 ACM GLOBAL LABORATORIES: COMPANY OVERVIEW
  • TABLE 304 ACM GLOBAL LABORATORIES: PRODUCTS/SERVICES OFFERED
  • TABLE 305 ACM GLOBAL LABORATORIES: DEALS, JANUARY 2022-JANUARY 2025
  • TABLE 306 WORLDWIDE CLINICAL TRIALS: COMPANY OVERVIEW
  • TABLE 307 VERSITI: COMPANY OVERVIEW
  • TABLE 308 CTI CLINICAL TRIAL & CONSULTING: COMPANY OVERVIEW
  • TABLE 309 CLARITY LABORATORIES, INC: COMPANY OVERVIEW
  • TABLE 310 NOVOTECH: COMPANY OVERVIEW
  • TABLE 311 ARUP LABORATORIES: COMPANY OVERVIEW
  • TABLE 312 PRECISION MEDICINE GROUP: COMPANY OVERVIEW
  • TABLE 313 BIOAGILYTIX LABS: COMPANY OVERVIEW
  • TABLE 314 CERBA HEALTHCARE: COMPANY OVERVIEW
  • TABLE 315 ALMAC GROUP: COMPANY OVERVIEW
  • TABLE 316 MLM MEDICAL LABS: COMPANY OVERVIEW
  • TABLE 317 SALVUS BIORESEARCH SOLUTIONS LLP: COMPANY OVERVIEW
  • TABLE 318 UNILABS: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 COMPANY REVENUE ESTIMATION APPROACH: BOTTOM-UP APPROACH
  • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 6 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: TOP-DOWN APPROACH
  • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • FIGURE 8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION)
  • FIGURE 11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 12 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 GEOGRAPHICAL SNAPSHOT OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
  • FIGURE 14 INCREASING PREVALENCE OF RARE DISEASES TO DRIVE MARKET
  • FIGURE 15 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT AND CHINA LED ASIA PACIFIC MARKET IN 2024
  • FIGURE 16 CHINA TO RECORD HIGHEST GROWTH RATE FROM 2025 TO 2030
  • FIGURE 17 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 18 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 20 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 21 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 22 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: INVESTMENT AND FUNDING SCENARIO, 2022-2025
  • FIGURE 23 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • FIGURE 25 KEY BUYING CRITERIA, BY END USER
  • FIGURE 26 AI USE CASES
  • FIGURE 27 NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET SNAPSHOT
  • FIGURE 28 ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET SNAPSHOT
  • FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2024 (USD MILLION)
  • FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
  • FIGURE 31 RANKING OF KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, 2024
  • FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025
  • FIGURE 33 FINANCIAL METRICS, 2025
  • FIGURE 34 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 35 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 36 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPANY FOOTPRINT
  • FIGURE 37 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 39 IQVIA: COMPANY SNAPSHOT (2024)
  • FIGURE 40 ICON PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 41 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023)
  • FIGURE 42 LABCORP: COMPANY SNAPSHOT (2024)
  • FIGURE 43 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2024)
  • FIGURE 44 MEDPACE: COMPANY SNAPSHOT (2024)
  • FIGURE 45 FRONTAGE LABS: COMPANY SNAPSHOT (2023)
  • FIGURE 46 SGS SOCIETE GENERALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2024)
  • FIGURE 47 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)